BioCryst Pharmaceuticals Inc
Here’s whether BioCryst Pharmaceuticals Inc (BCRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+7.27% over 10 days); RSI 53 — healthy momentum range; strong 1-year return of +31.6%; 3-month momentum positive (+42.6%). Concerns: declining volume on rally — weak conviction (0.72x 30d avg). Currently 16.0% off its 52-week high. Score: +6/7.
BCRX is in a confirmed uptrend, trading above both its 50-day ($8.56) and 200-day ($7.87) moving averages. An RSI of 53.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +31.6% compares to +35.1% for SPY (trailed the market by 3.5%).